13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q4 2017. See the latest, Q2 2026 →
Reported value
$1.26B
+53% on the quarter before
Positions
200
67 new · 12 sold out
Top 10
33.6%
of the value
Est. gain
+$26.5M
on stocks held all quarter
Est. return
+3.4%
on those stocks since Q3 2017
Positions as of Dec 31, 2017, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 60% of the reported value, each sized by its share, colored by what the fund did with it since Q3 2017. Striped tiles are options.
Largest buys
Since Q3 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Jd.Com Inc-ADR~$27.2MAdded · 0.1% → 2.2%+655,641 shares
- Tesla~$24.1MAdded · 2.6% → 3.5%+77,471 shares
- Stratasys Ltd~$24.0MAdded · 4.4% → 4.4%+1,203,256 shares
- Intellia Therapeutics Inc~$19.3MAdded · 1.1% → 2.1%+1,002,671 shares
- Athenahealth Inc~$18.0MAdded · 3.7% → 4.0%+135,383 shares
- Lendingclub Corp~$15.1MAdded · 1.6% → 1.9%+3,648,962 shares
- Medidata Solutions Inc~$14.1MAdded · 1.0% → 1.6%+221,799 shares
- Twitter Inc~$13.9MAdded · 3.4% → 4.2%+580,187 shares
- Aptiv Plc~$13.4MNew · 0.0% → 1.1%+157,806 shares
- Editas Medicine Inc~$13.1MAdded · 2.0% → 2.7%+424,975 shares
Largest sells
Since Q3 2017, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Akamai~$7.6MCut · 0.9% → 0.2%−117,062 shares
- Blackberry Ltd~$4.7MCut · 0.7% → 0.1%−417,198 shares
- Foundation Medicine Inc~$3.6MCut · 1.5% → 1.4%−53,183 shares
- Thermo Fisher Scientific Inc~$3.6MSold out · 0.4% → 0.0%−18,893 shares
- Twilio~$3.1MCut · 1.0% → 0.3%−130,796 shares
- Proto Labs Inc~$3.0MCut · 1.9% → 1.4%−28,793 shares
- Bluebird Bio Inc~$2.3MCut · 2.3% → 1.7%−13,069 shares
- Fanuc Corp-Unsp ADR~$2.3MCut · 0.5% → 0.2%−96,222 shares
- Exa Corp~$2.2MSold out · 0.3% → 0.0%−92,997 shares
- Mgi Digital Graphic Technolo~$2.0MSold out · 0.3% → 0.0%−32,651 shares
Holdings
As of Dec 31, 2017. Changes are in shares against Sep 30, 2017, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stratasys LtdCommon Stock · shares +77% · price −13.7% | 4.4% | $55.1M | −$4.9M | ||||||||
| Twitter IncCommon Stock · shares +35% · price +42.3% | 4.2% | $53.2M | +$11.7M | ||||||||
| AmazonCommon Stock · shares +22% · price +21.6% | 4.1% | $51.8M | +$7.6M | ||||||||
| Athenahealth IncCommon Stock · shares +55% · price +7.0% | 4.0% | $50.5M | +$2.1M | ||||||||
| TeslaCommon Stock · shares +122% · price −8.7% | 3.5% | $43.9M | −$1.9M | ||||||||
| Illumina IncCommon Stock · shares +32% · price +9.7% | 2.9% | $36.3M | +$2.4M | ||||||||
| BaiduADR · shares +57% · price −5.4% | 2.8% | $35.2M | −$1.3M | ||||||||
| Editas Medicine IncCommon Stock · shares +62% · price +28.0% | 2.7% | $34.2M | +$4.6M | ||||||||
| Juno Therapeutics IncCommon Stock · shares +31% · price +1.9% | 2.5% | $31.2M | +$443,284 | ||||||||
| NvidiaCommon Stock · shares −2.6% · price +8.2% | 2.4% | $30.5M | +$2.3M | ||||||||
| AlphabetCommon Stock · shares +49% · price +9.1% | 2.3% | $28.7M | +$1.6M | ||||||||
| Jd.Com Inc-ADRADR · shares +2,944% · price +8.4% | 2.2% | $28.1M | +$71,501 | ||||||||
| NetflixCommon Stock · shares +47% · price +5.9% | 2.1% | $26.7M | +$1.0M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +269% · price −22.7% | 2.1% | $26.4M | −$2.1M | ||||||||
| Lendingclub CorpCommon Stock · shares +169% · price −32.2% | 1.9% | $24.0M | −$4.2M | ||||||||
| 2u IncCommon Stock · shares +28% · price +15.1% | 1.9% | $23.7M | +$2.4M | ||||||||
| BlockCommon Stock · shares +107% · price +20.3% | 1.9% | $23.5M | +$1.9M | ||||||||
| SalesforceCommon Stock · shares +43% · price +9.4% | 1.9% | $23.3M | +$1.4M | ||||||||
| Tencent Holdings Ltd-Uns ADRADR · shares +43% · price +18.2% | 1.8% | $22.1M | +$2.4M | ||||||||
| Bluebird Bio IncCommon Stock · shares −9.7% · price +29.7% | 1.7% | $21.6M | +$4.9M | ||||||||
| MetaCommon Stock · shares +35% · price +3.3% | 1.6% | $20.7M | +$485,248 | ||||||||
| Medidata Solutions IncCommon Stock · shares +213% · price −18.8% | 1.6% | $20.7M | −$1.5M | ||||||||
| AppleCommon Stock · shares +112% · price +9.8% | 1.6% | $20.3M | +$858,092 | ||||||||
| Splunk IncCommon Stock · shares −3.3% · price +24.7% | 1.6% | $20.2M | +$4.0M | ||||||||
| Softbank Group Corp-Unsp ADRADR · shares +92% · price −2.2% | 1.5% | $19.3M | −$229,349 | ||||||||
| Total · 200 positions | 100% | $1.26B | +$26.5M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2017 to Q4 2017: 133 stocks held throughout, up $26.5M (+3.4%).
- Twitter Inc+$11.7M+42%
- Amazon+$7.6M+22%
- Foundation Medicine Inc+$7.2M+70%
- Bluebird Bio Inc+$4.9M+30%
- Editas Medicine Inc+$4.6M+28%
- Exone Co/The−$2.8M−26%
- Lendingclub Corp−$4.2M−32%
- Stratasys Ltd−$4.9M−14%
- Seres Therapeutics Inc−$5.3M−37%
- Bitcoin Investment Trust5:1 split−$23.4M−84%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 4 splits read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |